Brian Pollack, MD, PhD

Role

Dermatopathology
Specialty

Skin Cancer and Melanoma
Research Program

Cancer Immunology
Practicing Since

2006

Call 404-778-3333

Titles & Roles

Assistant Professor, Departments of Dermatology and Pathology

Emory University School of Medicine

Education & Training

Education

Fellowship, Dermatopathology, 2006
Emory University School of Medicine
Residency, Dermatology, 2005
Emory University School of Medicine
Internship, Internal Medicine, 2001
Mary Imogene Bassett Hospital
Medical Education, MD, 2000
University of Medicine & Dentistry of New Jersey

Board Certifications

Dermatology
American Board of Dermatology, 2006
Dermatopathology
American Board of Dermatology, 2006

Research

Publications

Title/Journal	Authors	Publication Date
Corrigendum to "Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma" [Journal of Controlled Release 357 (2023) 655-668]. Journal of controlled release : official journal of the Controlled Release Society	J Kim, PA Archer, MP Manspeaker, ARC Avecilla, BP Pollack, SN Thomas	02/01/2024
Obesity-induced dysregulation of skin-resident PPARγ⁺ Treg cells promotes IL-17A-mediated psoriatic inflammation. Immunity	P Sivasami, C Elkins, PP Diaz-Saldana, K Goss, A Peng, M Hamersky, J Bae, M Xu, BP Pollack, EM Horwitz, CD Scharer, L Seldin, C Li	08/08/2023
Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma. Journal of controlled release : official journal of the Controlled Release Society	J Kim, PA Archer, MP Manspeaker, ARC Avecilla, BP Pollack, SN Thomas	05/01/2023
Characteristics of the dermatologic cases on a popular crowdsourcing platform. Journal of the American Academy of Dermatology	MR McCrary, A Wu, BP Pollack	01/01/2023
Cutaneous findings in myotonic dystrophy. JAAD international	HE Kong, BP Pollack	06/01/2022
Cannabinoids in dermatologic surgery. Journal of the American Academy of Dermatology	HE Kong, BP Pollack, TW Blalock	12/01/2021
Critical role of interferons in gastrointestinal injury repair. Nature communications	C McElrath, V Espinosa, JD Lin, J Peng, R Sridhar, O Dutta, HC Tseng, SV Smirnov, H Risman, MJ Sandoval, V Davra, YJ Chang, BP Pollack, RB Birge, M Galan, A Rivera, JE Durbin, SV Kotenko	05/11/2021
Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers. Cancer research	S Lee, M Amgad, P Mobadersany, M McCormick, BP Pollack, H Elfandy, H Hussein, DA Gutman, LAD Cooper	02/15/2021
Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Science translational medicine	DM Francis, MP Manspeaker, A Schudel, LF Sestito, MJ O'Melia, HT Kissick, BP Pollack, EK Waller, SN Thomas	09/30/2020
Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. Molecular cancer research : MCR	S Chandrasekaran, M Sasaki, CD Scharer, HT Kissick, DG Patterson, KR Magliocca, JT Seykora, B Sapkota, DA Gutman, LA Cooper, GB Lesinski, EK Waller, SN Thomas, SV Kotenko, JM Boss, CS Moreno, RA Swerlick, BP Pollack	12/01/2019
Palladium based nanoparticles for the treatment of advanced melanoma. Scientific reports	J Elsey, JA Bubley, L Zhu, S Rao, M Sasaki, BP Pollack, L Yang, JL Arbiser	03/01/2019
Propranolol exhibits activity against hemangiomas independent of beta blockade. NPJ precision oncology	M Sasaki, PE North, J Elsey, J Bubley, S Rao, Y Jung, S Wu, MH Zou, BP Pollack, J Kumar, H Singh, JL Arbiser	01/01/2019
Reversible secretome and signaling defects in diabetic mesenchymal stem cells from peripheral arterial disease patients. Journal of vascular surgery	T Chadid, A Morris, A Surowiec, S Robinson, M Sasaki, J Galipeau, BP Pollack, LP Brewster	12/01/2018
Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. Journal of clinical pharmacology	AE Kersh, S Ng, YM Chang, M Sasaki, SN Thomas, HT Kissick, GB Lesinski, RR Kudchadkar, EK Waller, BP Pollack	01/01/2018
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF^V600E in human cancers. The Journal of biological chemistry	L Zhao, J Fan, S Xia, Y Pan, S Liu, G Qian, Z Qian, HB Kang, JL Arbiser, BP Pollack, RR Kudchadkar, DH Lawson, M Rossi, O Abdel-Wahab, T Merghoub, HJ Khoury, FR Khuri, LH Boise, S Lonial, F Chen, J Chen, R Lin	06/16/2017
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma management	MM Johnson, SA Leachman, LG Aspinwall, LD Cranmer, C Curiel-Lewandrowski, VK Sondak, CE Stemwedel, SM Swetter, J Vetto, T Bowles, RP Dellavalle, LJ Geskin, D Grossman, KF Grossmann, JE Hawkes, JM Jeter, CC Kim, JM Kirkwood, AR Mangold, F Meyskens, ME Ming, KC Nelson, M Piepkorn, BP Pollack, JK Robinson, AJ Sober, S Trotter, SS Venna, S Agarwala, R Alani, B Averbook, A Bar, M Becevic, N Box, W E Carson, PB Cassidy, SC Chen, EY Chu, DL Ellis, LK Ferris, DE Fisher, K Kendra, DH Lawson, PD Leming, KA Margolin, S Markovic, MC Martini, D Miller, D Sahni, WH Sharfman, J Stein, AJ Stratigos, A Tarhini, MH Taylor, OJ Wisco, MK Wong	03/01/2017
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell metabolism	S Xia, R Lin, L Jin, L Zhao, HB Kang, Y Pan, S Liu, G Qian, Z Qian, E Konstantakou, B Zhang, JT Dong, YR Chung, O Abdel-Wahab, T Merghoub, L Zhou, RR Kudchadkar, DH Lawson, HJ Khoury, FR Khuri, LH Boise, S Lonial, BH Lee, BP Pollack, JL Arbiser, J Fan, QY Lei, J Chen	02/07/2017
Effective local anesthesia for onabotulinumtoxin A injections to treat hyperhidrosis associated with traumatic amputation. Dermatology online journal	LL Shi, MR Sargen, SC Chen, JL Arbiser, BP Pollack	06/15/2016
Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival. Asian journal of urology	RR Sekar, CM De La Calle, D Patil, SA Holzman, Y Baum, U Sheikh, JH Huang, AO Osunkoya, BP Pollack, HT Kissick, K Ogan, VA Master	04/01/2016
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. Frontiers in pharmacology	AE Kersh, M Sasaki, LA Cooper, HT Kissick, BP Pollack	01/01/2016
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular cell	HB Kang, J Fan, R Lin, S Elf, Q Ji, L Zhao, L Jin, JH Seo, C Shan, JL Arbiser, C Cohen, D Brat, HM Miziorko, E Kim, O Abdel-Wahab, T Merghoub, S Fröhling, C Scholl, P Tamayo, DA Barbie, L Zhou, BP Pollack, K Fisher, RR Kudchadkar, DH Lawson, G Sica, M Rossi, S Lonial, HJ Khoury, FR Khuri, BH Lee, TJ Boggon, C He, S Kang, J Chen	08/06/2015
Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor. Scientific reports	JA Pulit-Penaloza, B Sapkota, E Stein Esser, RW Compans, BP Pollack, I Skountzou	07/31/2015
Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. American journal of clinical oncology	D Okwan-Duodu, BP Pollack, D Lawson, MK Khan	02/01/2015
Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity. Journal of virology	GS Mohan, L Ye, W Li, A Monteiro, X Lin, B Sapkota, BP Pollack, RW Compans, C Yang	01/15/2015
High Expression of Major Histocompatibility Complex Class I in Clear Cell Renal Cell Carcinoma Is Associated with Improved Prognosis. Urologia internationalis	SA Holzman, CM de la Calle, HT Kissick, AO Osunkoya, BP Pollack, D Patil, K Ogan, VA Master	01/01/2015
A protective role of murine langerin⁺ cells in immune responses to cutaneous vaccination with microneedle patches. Scientific reports	JA Pulit-Penaloza, ES Esser, EV Vassilieva, JW Lee, MT Taherbhai, BP Pollack, MR Prausnitz, RW Compans, I Skountzou	08/18/2014
Vemurafenib enhances MHC induction in BRAF^V600E homozygous melanoma cells. Oncoimmunology	B Sapkota, CE Hill, BP Pollack	01/01/2013
EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers? Oncoimmunology	BP Pollack	01/01/2012
Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity. Journal of immunology (Baltimore, Md. : 1950)	MS Hossain, DL Jaye, BP Pollack, AB Farris, ML Tselanyane, E David, JD Roback, AT Gewirtz, EK Waller	11/15/2011
Melanoma survival in the United States, 1992 to 2005. Journal of the American Academy of Dermatology	LA Pollack, J Li, Z Berkowitz, HK Weir, XC Wu, UA Ajani, DU Ekwueme, C Li, BP Pollack	11/01/2011
Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clinical cancer research : an official journal of the American Association for Cancer Research	BP Pollack, B Sapkota, TV Cartee	07/01/2011
Low abundance of sweat duct Cl- channel CFTR in both healthy and cystic fibrosis athletes with exceptionally salty sweat during exercise. American journal of physiology. Regulatory, integrative and comparative physiology	MB Brown, KK Haack, BP Pollack, M Millard-Stafford, NA McCarty	03/01/2011
Activating transcription factor 3 (ATF3) expression is increased in erythema multiforme and is regulated by IFN-gamma in human keratinocytes. Experimental dermatology	BP Pollack, B Sapkota, PL Haun	08/01/2010
Ultraviolet radiation-induced transcription is associated with gene-specific histone acetylation. Photochemistry and photobiology	BP Pollack, B Sapkota, JM Boss	01/01/2009
Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. American journal of kidney diseases : the official journal of the National Kidney Foundation	AJ Kallen, MA Jhung, S Cheng, T Hess, G Turabelidze, L Abramova, M Arduino, J Guarner, B Pollack, G Saab, PR Patel	06/01/2008
Chronic GvHD decreases antiviral immune responses in allogeneic BMT. Blood	MS Hossain, JD Roback, BP Pollack, DL Jaye, A Langston, EK Waller	05/15/2007

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.